Cargando…
Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
With a decade left to reach the ambitious goals for viral hepatitis elimination set out by the World Health Organization, many challenges remain. Despite the remarkable improvements in therapy for hepatitis C virus (HCV) infection, most people living with the infection remain undiagnosed, and only a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183173/ https://www.ncbi.nlm.nih.gov/pubmed/34141979 http://dx.doi.org/10.1002/hep4.1731 |
_version_ | 1783704330263592960 |
---|---|
author | Feld, Jordan J. Ward, John W. |
author_facet | Feld, Jordan J. Ward, John W. |
author_sort | Feld, Jordan J. |
collection | PubMed |
description | With a decade left to reach the ambitious goals for viral hepatitis elimination set out by the World Health Organization, many challenges remain. Despite the remarkable improvements in therapy for hepatitis C virus (HCV) infection, most people living with the infection remain undiagnosed, and only a fraction have received curative therapy. Accordingly, the 2020 HCV Special Interest Group symposium at the annual American Association for the Study of Liver Diseases Liver Meeting examined policies and strategies for the scale‐up of HCV testing and expanded access to HCV care and treatment outside the specialty setting, including primary care and drug treatment and settings for care of persons who inject drugs and other marginalized populations at risk for HCV infection. The importance of these paradigms in elimination efforts, including micro‐elimination strategies, was explored, and the session also included discussion of hepatitis C vaccine development and other strategies to reduce mortality through the use of organs from HCV‐infected organ donors for HCV‐negative recipients. In this review, the key concepts raised at this important symposium are summarized. |
format | Online Article Text |
id | pubmed-8183173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81831732021-06-16 Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020 Feld, Jordan J. Ward, John W. Hepatol Commun Reviews With a decade left to reach the ambitious goals for viral hepatitis elimination set out by the World Health Organization, many challenges remain. Despite the remarkable improvements in therapy for hepatitis C virus (HCV) infection, most people living with the infection remain undiagnosed, and only a fraction have received curative therapy. Accordingly, the 2020 HCV Special Interest Group symposium at the annual American Association for the Study of Liver Diseases Liver Meeting examined policies and strategies for the scale‐up of HCV testing and expanded access to HCV care and treatment outside the specialty setting, including primary care and drug treatment and settings for care of persons who inject drugs and other marginalized populations at risk for HCV infection. The importance of these paradigms in elimination efforts, including micro‐elimination strategies, was explored, and the session also included discussion of hepatitis C vaccine development and other strategies to reduce mortality through the use of organs from HCV‐infected organ donors for HCV‐negative recipients. In this review, the key concepts raised at this important symposium are summarized. John Wiley and Sons Inc. 2021-05-03 /pmc/articles/PMC8183173/ /pubmed/34141979 http://dx.doi.org/10.1002/hep4.1731 Text en © 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Reviews Feld, Jordan J. Ward, John W. Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020 |
title | Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
|
title_full | Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
|
title_fullStr | Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
|
title_full_unstemmed | Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
|
title_short | Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
|
title_sort | key elements on the pathway to hcv elimination: lessons learned from the aasld hcv special interest group 2020 |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183173/ https://www.ncbi.nlm.nih.gov/pubmed/34141979 http://dx.doi.org/10.1002/hep4.1731 |
work_keys_str_mv | AT feldjordanj keyelementsonthepathwaytohcveliminationlessonslearnedfromtheaasldhcvspecialinterestgroup2020 AT wardjohnw keyelementsonthepathwaytohcveliminationlessonslearnedfromtheaasldhcvspecialinterestgroup2020 |